<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00696761</url>
  </required_header>
  <id_info>
    <org_study_id>L9990</org_study_id>
    <nct_id>NCT00696761</nct_id>
  </id_info>
  <brief_title>The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients</brief_title>
  <official_title>The Long Term Effects of Alfuzosin(Xatral XL) in LUTS/BPH Patients: Evaluation of Voiding and Storage Function According to Bladder Outlet Obstruction Grade and Bladder Contractility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Benign prostatic hyperplasia (BPH) is a common condition among older men. The efficacy of&#xD;
      α1-blockers for treating BPH has been well documented and they are recommended for the&#xD;
      treatment of BPH by clinical guidelines.&#xD;
&#xD;
      It is not well known if a stratification based on the grade of BOO and bladder contractility&#xD;
      has any predictive value for patients who are treated with an α1-selective blocking agent. In&#xD;
      our study, we investigated possible differences in treatment outcome between patients with&#xD;
      and without BOO, and with or without proper contractility who are treated with alfuzosin. So&#xD;
      we will compare the quantified improvements 12 months after alfuzosin medication in LUTS/BPH&#xD;
      patients by the grade of BOO and/or bladder contractility.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Primary objective To evaluate efficacy on voiding and storage symptoms in LUTS/BPH&#xD;
           patients after 12 months of treatment with Xatral XL® by the grade of bladder outlet&#xD;
           obstruction and/or bladder contractility&#xD;
&#xD;
        2. Secondary objectives To evaluate efficacy on voiding and storage symptoms in LUTS/BPH&#xD;
           patients after 3 months and 6 months of treatment with Xatral XL® by the grade of&#xD;
           bladder outlet obstruction and/or bladder contractility To evaluate efficacy on maximal&#xD;
           flow rate (MFR) and post-voided residual urine (PVR) To evaluate on voiding frequency,&#xD;
           urgency severity &amp; frequency, and nocturia To evaluate patient tolerability to the&#xD;
           medication To evaluate global impression of improvement (GII)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome; International Prostate Symptom Score Changes Between 4 Groups Compared to Baseline After 12 mo Treatment</measure>
    <time_frame>12months</time_frame>
    <description>international prostate symptom score was measured at baseline and 12 months. total scores on a scale range (from 0 to 35) higher values represent a worse outcome&#xD;
Baseline score minus 12-month score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Efficacy Was Analyzed by Validated Symptom Scores.</measure>
    <time_frame>12 month</time_frame>
    <description>Alfuzosin was administered daily (10 mg). After 12 months of treatment, efficacy and safety were analyzed. Efficacy was measured by validated symptom scores (using IPSS ). IPSS score change was measured pre- and post- treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of International Continence Society (ICS)-Male Questionnaire (Voiding Sum)</measure>
    <time_frame>12months</time_frame>
    <description>Changes of International Continence Society (ICS)-male questionnaire (voiding sum) to measure the efficacy of alfuzosin 10mg at 12 months post-treatment.&#xD;
Range 0-20, higher scores represent worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Peak Flow Rates on Uroflowmetry</measure>
    <time_frame>12 months</time_frame>
    <description>Changes of peak flow rates on uroflowmetry to measure the efficacy of alfuzosin 10mg at 12 months post-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Residual Urine Volumes</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in residual urine volumes to measure the efficacy of alfuzosin 10mg at 12 months post-treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">232</enrollment>
  <condition>BPH</condition>
  <arm_group>
    <arm_group_label>group1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bladder outlet obstruction index(BOOI)≥ 20, Bladder contractility index(BCI)≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BOOI≥ 20, BCI&lt;100 Alfuzosin was administered daily (10 mg) for 12 month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BOOI&lt;20, BCI≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BOOI&lt;20, BCI&lt;100 Alfuzosin was administered daily (10 mg) for 12 month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfuzosin</intervention_name>
    <description>10mg, once daily, 12months</description>
    <arm_group_label>group1</arm_group_label>
    <other_name>xatral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfuzosin</intervention_name>
    <description>10mg, once daily, 12months</description>
    <arm_group_label>group2</arm_group_label>
    <other_name>xatral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfuzosin</intervention_name>
    <description>10mg, once daily, 12months</description>
    <arm_group_label>group 3</arm_group_label>
    <other_name>xatral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfuzosin</intervention_name>
    <description>10mg, once daily, 12months</description>
    <arm_group_label>group 4</arm_group_label>
    <other_name>xatral</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ambulatory males (≥50 years) suffering from LUTS suggestive of BPH&#xD;
&#xD;
          -  Patients satisfying all of the following:&#xD;
&#xD;
          -  Moderate to severe LUTS :&#xD;
&#xD;
          -  international prostate symptom score (IPSS)≥ 8&#xD;
&#xD;
          -  An enlarged prostate (≥25 mL)&#xD;
&#xD;
          -  Decreased peak flow rate : Qmax ≤15 mL/s (volume voided ≥ 120 mL)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Post voided residual urine ≥ 200 mL&#xD;
&#xD;
          -  Patients performing catheterization&#xD;
&#xD;
          -  Urinary tract infection patients&#xD;
&#xD;
          -  Patients taking 5 alpha reductase inhibitor&#xD;
&#xD;
          -  Known hypersensitivity to alfuzosin&#xD;
&#xD;
          -  History of postural hypotension or syncope&#xD;
&#xD;
          -  Hypertension patients treated with other alpha1-blockers&#xD;
&#xD;
          -  Patients newly taking anticholinergic medication within 1 month&#xD;
&#xD;
          -  Hepatic insufficiency (Aspartate transaminase /alanine aminotransferase ≥ 2 times of&#xD;
             normal range)&#xD;
&#xD;
          -  Renal insufficiency (s-Cr ≥ 2mg/dL)&#xD;
&#xD;
          -  Unstable angina pectoris&#xD;
&#xD;
          -  Uninvestigated hematuria&#xD;
&#xD;
          -  Serum Prostate specific antigen ≥ 4 ng/mL (biopsy proven no cancer patients can be&#xD;
             included)&#xD;
&#xD;
          -  Interstitial cystitis patients&#xD;
&#xD;
          -  Severe concomitant condition threatening life.&#xD;
&#xD;
          -  Patient who is unable to make voiding diary&#xD;
&#xD;
          -  Bladder or prostate cancer patients&#xD;
&#xD;
          -  Patients receiving prostate or bladder surgery&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myung-Soo Choo, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>From the Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea</affiliation>
  </overall_official>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 11, 2008</study_first_submitted>
  <study_first_submitted_qc>June 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2008</study_first_posted>
  <results_first_submitted>July 22, 2013</results_first_submitted>
  <results_first_submitted_qc>January 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 4, 2014</results_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Myung-Soo Choo</investigator_full_name>
    <investigator_title>urology department</investigator_title>
  </responsible_party>
  <keyword>LUTS</keyword>
  <keyword>BPH</keyword>
  <keyword>bladder outlet obstruction</keyword>
  <keyword>bladder contractility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neck Obstruction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alfuzosin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited from a specialty clinic at the Asan Medical Center, Samsung Medical Center,The Catholic University of Korea College of Medicine, Hallym University, Chuncheon, Korea for 12-month</recruitment_details>
      <pre_assignment_details>232 participants recruited; 276 screened, 44 excluded</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BOOI≥20, BCI≥ 100</title>
          <description>Bladder outlet obstruction index(BOOI)≥ 20, bladder contractility index (BCI)≥ 100&#xD;
alfuzosin : 10mg, once daily, 12months</description>
        </group>
        <group group_id="P2">
          <title>BOOI≥20, BCI&lt; 100</title>
          <description>BOOI≥ 20, BCI&lt;100&#xD;
alfuzosin : 10mg, once daily, 12months</description>
        </group>
        <group group_id="P3">
          <title>BOOI&lt;20, BCI≥ 100</title>
          <description>BOOI&lt;20, BCI≥ 100)&#xD;
alfuzosin : 10mg, once daily, 12months</description>
        </group>
        <group group_id="P4">
          <title>BOOI&lt;20, BCI&lt; 100</title>
          <description>BOOI&lt;20, BCI&lt;100&#xD;
alfuzosin : 10mg, once daily, 12 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 3</title>
          <description>BOOI&lt;20, BCI≥ 100)&#xD;
alfuzosin : 10mg, once daily, 12months</description>
        </group>
        <group group_id="B2">
          <title>Group 4</title>
          <description>BOOI&lt;20, BCI&lt;100&#xD;
alfuzosin : 10mg, once daily, 12 months</description>
        </group>
        <group group_id="B3">
          <title>group1</title>
          <description>BOOI≥ 20, BCI≥ 100&#xD;
alfuzosin : 10mg, once daily, 12months</description>
        </group>
        <group group_id="B4">
          <title>group2</title>
          <description>BOOI≥ 20, BCI&lt;100&#xD;
alfuzosin : 10mg, once daily, 12months</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="61"/>
            <count group_id="B4" value="76"/>
            <count group_id="B5" value="232"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.0" spread="2.0"/>
                    <measurement group_id="B2" value="67.4" spread="0"/>
                    <measurement group_id="B3" value="66.0" spread="1.2"/>
                    <measurement group_id="B4" value="63.1" spread="5"/>
                    <measurement group_id="B5" value="65.7" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="76"/>
                    <measurement group_id="B5" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="76"/>
                    <measurement group_id="B5" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>international prostate symptom score</title>
          <description>higher values represent a worse outcome total score range (form 0 to 35)</description>
          <units>scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.9" spread="7.6"/>
                    <measurement group_id="B2" value="18.8" spread="6.8"/>
                    <measurement group_id="B3" value="19.4" spread="6.9"/>
                    <measurement group_id="B4" value="21.0" spread="6.5"/>
                    <measurement group_id="B5" value="19.5" spread="6.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Outcome; International Prostate Symptom Score Changes Between 4 Groups Compared to Baseline After 12 mo Treatment</title>
        <description>international prostate symptom score was measured at baseline and 12 months. total scores on a scale range (from 0 to 35) higher values represent a worse outcome&#xD;
Baseline score minus 12-month score</description>
        <time_frame>12months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BOOI≥ 20, BCI≥100</title>
            <description>Bladder outlet obstruction index(BOOI)≥ 20, Bladder contractility index(BCI)≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.&#xD;
alfuzosin: 10mg, once daily, 12months</description>
          </group>
          <group group_id="O2">
            <title>BOOI≥ 20, BCI&lt;100</title>
            <description>BOOI≥ 20, BCI&lt;100 Alfuzosin was administered daily (10 mg) for 12 month.&#xD;
alfuzosin: 10mg, once daily, 12months</description>
          </group>
          <group group_id="O3">
            <title>BOOI&lt;20, BCI≥ 100</title>
            <description>BOOI&lt;20, BCI≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.&#xD;
alfuzosin: 10mg, once daily, 12months</description>
          </group>
          <group group_id="O4">
            <title>BOOI&lt;20, BCI&lt;100</title>
            <description>BOOI&lt;20, BCI&lt;100 Alfuzosin was administered daily (10 mg) for 12 month.&#xD;
alfuzosin: 10mg, once daily, 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Outcome; International Prostate Symptom Score Changes Between 4 Groups Compared to Baseline After 12 mo Treatment</title>
          <description>international prostate symptom score was measured at baseline and 12 months. total scores on a scale range (from 0 to 35) higher values represent a worse outcome&#xD;
Baseline score minus 12-month score</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" spread="6.6"/>
                    <measurement group_id="O2" value="12.0" spread="5.4"/>
                    <measurement group_id="O3" value="10.6" spread="6.1"/>
                    <measurement group_id="O4" value="13.4" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment Efficacy Was Analyzed by Validated Symptom Scores.</title>
        <description>Alfuzosin was administered daily (10 mg). After 12 months of treatment, efficacy and safety were analyzed. Efficacy was measured by validated symptom scores (using IPSS ). IPSS score change was measured pre- and post- treatment.</description>
        <time_frame>12 month</time_frame>
        <population>The population analyzed included participants receiving drug for 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3</title>
            <description>BOOI&lt;20, BCI≥ 100)&#xD;
alfuzosin : 10mg, once daily, 12months</description>
          </group>
          <group group_id="O2">
            <title>Group 4</title>
            <description>BOOI&lt;20, BCI&lt;100&#xD;
alfuzosin : 10mg, once daily, 12 months</description>
          </group>
          <group group_id="O3">
            <title>group1</title>
            <description>BOOI≥ 20, BCI≥ 100&#xD;
alfuzosin : 10mg, once daily, 12months</description>
          </group>
          <group group_id="O4">
            <title>group2</title>
            <description>BOOI≥ 20, BCI&lt;100&#xD;
alfuzosin : 10mg, once daily, 12months</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Efficacy Was Analyzed by Validated Symptom Scores.</title>
          <description>Alfuzosin was administered daily (10 mg). After 12 months of treatment, efficacy and safety were analyzed. Efficacy was measured by validated symptom scores (using IPSS ). IPSS score change was measured pre- and post- treatment.</description>
          <population>The population analyzed included participants receiving drug for 12 months</population>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="6.2"/>
                    <measurement group_id="O2" value="6.4" spread="6.2"/>
                    <measurement group_id="O3" value="6.4" spread="6.5"/>
                    <measurement group_id="O4" value="9.0" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The Kruskal-Wallis test, analysis of variance, and the Wilcoxon signed rank-sum test were used to compare changes from baseline to endpoint after treatment.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes of International Continence Society (ICS)-Male Questionnaire (Voiding Sum)</title>
        <description>Changes of International Continence Society (ICS)-male questionnaire (voiding sum) to measure the efficacy of alfuzosin 10mg at 12 months post-treatment.&#xD;
Range 0-20, higher scores represent worse outcomes.</description>
        <time_frame>12months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>group1</title>
            <description>Bladder outlet obstruction index(BOOI)≥ 20, Bladder contractility index(BCI)≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.&#xD;
Alfuzosin: 10mg, once daily, 12months</description>
          </group>
          <group group_id="O2">
            <title>group2</title>
            <description>BOOI≥ 20, BCI&lt;100 Alfuzosin was administered daily (10 mg) for 12 month.&#xD;
Alfuzosin: 10mg, once daily, 12months</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>BOOI&lt;20, BCI≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.&#xD;
Alfuzosin: 10mg, once daily, 12months</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>BOOI&lt;20, BCI&lt;100 Alfuzosin was administered daily (10 mg) for 12 month.&#xD;
Alfuzosin: 10mg, once daily, 12months</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of International Continence Society (ICS)-Male Questionnaire (Voiding Sum)</title>
          <description>Changes of International Continence Society (ICS)-male questionnaire (voiding sum) to measure the efficacy of alfuzosin 10mg at 12 months post-treatment.&#xD;
Range 0-20, higher scores represent worse outcomes.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="4.3"/>
                    <measurement group_id="O2" value="7.2" spread="3.4"/>
                    <measurement group_id="O3" value="9.7" spread="6.4"/>
                    <measurement group_id="O4" value="8.2" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes of Peak Flow Rates on Uroflowmetry</title>
        <description>Changes of peak flow rates on uroflowmetry to measure the efficacy of alfuzosin 10mg at 12 months post-treatment.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>group1</title>
            <description>Bladder outlet obstruction index(BOOI)≥ 20, Bladder contractility index(BCI)≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.&#xD;
Alfuzosin: 10mg, once daily, 12months</description>
          </group>
          <group group_id="O2">
            <title>group2</title>
            <description>BOOI≥ 20, BCI&lt;100 Alfuzosin was administered daily (10 mg) for 12 month.&#xD;
Alfuzosin: 10mg, once daily, 12months</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>BOOI&lt;20, BCI≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.&#xD;
Alfuzosin: 10mg, once daily, 12months</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>BOOI&lt;20, BCI&lt;100 Alfuzosin was administered daily (10 mg) for 12 month.&#xD;
Alfuzosin: 10mg, once daily, 12months</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of Peak Flow Rates on Uroflowmetry</title>
          <description>Changes of peak flow rates on uroflowmetry to measure the efficacy of alfuzosin 10mg at 12 months post-treatment.</description>
          <units>ml/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="7.2"/>
                    <measurement group_id="O2" value="10.9" spread="6.4"/>
                    <measurement group_id="O3" value="16.8" spread="8.7"/>
                    <measurement group_id="O4" value="13.0" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Residual Urine Volumes</title>
        <description>Changes in residual urine volumes to measure the efficacy of alfuzosin 10mg at 12 months post-treatment.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>group1</title>
            <description>Bladder outlet obstruction index(BOOI)≥ 20, Bladder contractility index(BCI)≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.&#xD;
Alfuzosin: 10mg, once daily, 12months</description>
          </group>
          <group group_id="O2">
            <title>group2</title>
            <description>BOOI≥ 20, BCI&lt;100 Alfuzosin was administered daily (10 mg) for 12 month.&#xD;
Alfuzosin: 10mg, once daily, 12months</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>BOOI&lt;20, BCI≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.&#xD;
Alfuzosin: 10mg, once daily, 12months</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>BOOI&lt;20, BCI&lt;100 Alfuzosin was administered daily (10 mg) for 12 month.&#xD;
Alfuzosin: 10mg, once daily, 12months</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Residual Urine Volumes</title>
          <description>Changes in residual urine volumes to measure the efficacy of alfuzosin 10mg at 12 months post-treatment.</description>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.6" spread="87"/>
                    <measurement group_id="O2" value="37" spread="45.2"/>
                    <measurement group_id="O3" value="29.3" spread="35.9"/>
                    <measurement group_id="O4" value="31.7" spread="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 3</title>
          <description>BOOI&lt;20, BCI≥ 100)&#xD;
alfuzosin : 10mg, once daily, 12months</description>
        </group>
        <group group_id="E2">
          <title>Group 4</title>
          <description>BOOI&lt;20, BCI&lt;100&#xD;
alfuzosin : 10mg, once daily, 12 months</description>
        </group>
        <group group_id="E3">
          <title>group1</title>
          <description>BOOI≥ 20, BCI≥ 100&#xD;
alfuzosin : 10mg, once daily, 12months</description>
        </group>
        <group group_id="E4">
          <title>group2</title>
          <description>BOOI≥ 20, BCI&lt;100&#xD;
alfuzosin : 10mg, once daily, 12months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3.9</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Patients were not divided into three groups according to the ICS nomogram (obstructed [BOOI &lt;40], equivocally obstructed (20 &lt;BOOI &lt;40), and unobstructed [BOOI &lt;20]).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kanghyon Song, Myung-Soo Choo, Kyu-Sung Lee, Ji-Yeon Han, Young-Suk Lee,</name_or_title>
      <organization>the Department of Urology, Asan Medical Center, University of Ulsan College</organization>
      <phone>82-2-3010-3735</phone>
      <email>mschoo@amc.seoul.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

